Moleculin Biotech (MBRX) Projected to Post Quarterly Earnings on Friday

Moleculin Biotech (NASDAQ:MBRX) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of ($0.71) per share for the quarter.

Moleculin Biotech Trading Down 4.7 %

Shares of Moleculin Biotech stock opened at $1.01 on Friday. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $5.44. The company has a 50-day moving average of $1.02 and a 200 day moving average of $1.69.

Analyst Ratings Changes

A number of research firms have weighed in on MBRX. Maxim Group upgraded shares of Moleculin Biotech from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Tuesday, March 25th. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Moleculin Biotech in a research note on Monday, March 24th. Finally, StockNews.com upgraded Moleculin Biotech to a “sell” rating in a research note on Wednesday, March 26th.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.